S&P 500   2,739.29 (+3.00%)
DOW   23,327.31 (+2.97%)
QQQ   200.06 (+1.86%)
AAPL   265.12 (+2.19%)
FB   173.21 (+2.59%)
MSFT   164.95 (+0.89%)
AMZN   2,031.83 (+1.01%)
CGC   14.94 (+3.03%)
NVDA   267.28 (+3.19%)
BABA   195.28 (-1.37%)
MU   48.22 (+3.61%)
GE   7.33 (+4.12%)
TSLA   547.44 (+0.36%)
AMD   48.84 (+2.69%)
T   29.54 (-1.80%)
ACB   0.85 (+6.28%)
F   5.01 (+6.37%)
BAC   23.15 (+4.56%)
GILD   74.33 (-0.46%)
PRI   96.27 (+9.45%)
S&P 500   2,739.29 (+3.00%)
DOW   23,327.31 (+2.97%)
QQQ   200.06 (+1.86%)
AAPL   265.12 (+2.19%)
FB   173.21 (+2.59%)
MSFT   164.95 (+0.89%)
AMZN   2,031.83 (+1.01%)
CGC   14.94 (+3.03%)
NVDA   267.28 (+3.19%)
BABA   195.28 (-1.37%)
MU   48.22 (+3.61%)
GE   7.33 (+4.12%)
TSLA   547.44 (+0.36%)
AMD   48.84 (+2.69%)
T   29.54 (-1.80%)
ACB   0.85 (+6.28%)
F   5.01 (+6.37%)
BAC   23.15 (+4.56%)
GILD   74.33 (-0.46%)
PRI   96.27 (+9.45%)
S&P 500   2,739.29 (+3.00%)
DOW   23,327.31 (+2.97%)
QQQ   200.06 (+1.86%)
AAPL   265.12 (+2.19%)
FB   173.21 (+2.59%)
MSFT   164.95 (+0.89%)
AMZN   2,031.83 (+1.01%)
CGC   14.94 (+3.03%)
NVDA   267.28 (+3.19%)
BABA   195.28 (-1.37%)
MU   48.22 (+3.61%)
GE   7.33 (+4.12%)
TSLA   547.44 (+0.36%)
AMD   48.84 (+2.69%)
T   29.54 (-1.80%)
ACB   0.85 (+6.28%)
F   5.01 (+6.37%)
BAC   23.15 (+4.56%)
GILD   74.33 (-0.46%)
PRI   96.27 (+9.45%)
S&P 500   2,739.29 (+3.00%)
DOW   23,327.31 (+2.97%)
QQQ   200.06 (+1.86%)
AAPL   265.12 (+2.19%)
FB   173.21 (+2.59%)
MSFT   164.95 (+0.89%)
AMZN   2,031.83 (+1.01%)
CGC   14.94 (+3.03%)
NVDA   267.28 (+3.19%)
BABA   195.28 (-1.37%)
MU   48.22 (+3.61%)
GE   7.33 (+4.12%)
TSLA   547.44 (+0.36%)
AMD   48.84 (+2.69%)
T   29.54 (-1.80%)
ACB   0.85 (+6.28%)
F   5.01 (+6.37%)
BAC   23.15 (+4.56%)
GILD   74.33 (-0.46%)
PRI   96.27 (+9.45%)
Log in

NASDAQ:AMGNAmgen Stock Price, Forecast & News

$215.86
+7.08 (+3.39 %)
(As of 04/8/2020 02:43 PM ET)
Add
Compare
Today's Range
$207.34
Now: $215.86
$215.86
50-Day Range
$182.24
MA: $205.60
$223.48
52-Week Range
$166.30
Now: $215.86
$244.99
Volume1.09 million shs
Average Volume3.22 million shs
Market Capitalization$127.32 billion
P/E Ratio16.77
Dividend Yield3.02%
Beta0.9
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
Amgen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.54 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.36 billion
Cash Flow$19.88 per share
Book Value$16.28 per share

Profitability

Net Income$7.84 billion

Miscellaneous

Employees23,400
Market Cap$127.32 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.


Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 6.8% and is now trading at $212.23. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its earnings results on Thursday, January, 30th. The medical research company reported $3.64 earnings per share for the quarter, beating analysts' consensus estimates of $3.47 by $0.17. The medical research company earned $6.20 billion during the quarter, compared to analyst estimates of $6.04 billion. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The firm's revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.42 earnings per share. View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, March 4th. Stockholders of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Friday, May 15th. View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.

What price target have analysts set for AMGN?

26 analysts have issued twelve-month price targets for Amgen's stock. Their forecasts range from $185.00 to $277.00. On average, they expect Amgen's stock price to reach $238.70 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price. View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
  • 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
  • 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)

Has Amgen been receiving favorable news coverage?

Headlines about AMGN stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amgen earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAmgen.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), Cisco Systems (CSCO), Pfizer (PFE), Gilead Sciences (GILD) and Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Gradient Investments LLC (0.01%), Cullinan Associates Inc. (0.01%), F&V Capital Management LLC (0.00%), American National Bank (0.00%) and McGuire Investment Group LLC (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Lake Street Financial LLC, Cullinan Associates Inc., Pensionfund DSM Netherlands, IMS Capital Management, Xcel Wealth Management LLC, Thomasville National Bank, Fulcrum Equity Management, and Triangle Securities Wealth Management. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including IBM Retirement Fund, State of Alaska Department of Revenue, Mountain Pacific Investment Advisers Inc. ID, American National Bank, Birch Capital Management LLC, F&V Capital Management LLC, Orrstown Financial Services Inc., and M&R Capital Management Inc.. View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $212.23.

How big of a company is Amgen?

Amgen has a market capitalization of $125.17 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe. View additional information about Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel